CCF Webinar: Investigational treatment for KRAS-Mutated Cholangiocarcinoma – An Unmet Need

There are currently no approved therapies for patients with KRAS-mutated cholangiocarcinoma. In this webinar, you will learn about an ongoing Phase 1b/2a study that is aimed to evaluate the combination of GNS561, an autophagy inhibitor, and trametinib, a MEK-inhibitor, as a potential novel treatment for patients with unresectable or metastatic KRAS-mutated cholangiocarcinoma.